Vaxxinity announces positive target engagement data from phase 1 clinical trial for parkinson's disease at ad/pd™ 2024

Ub-312 is first immunotherapy to show reduction of pathological alpha-synuclein in cerebrospinal fluid of parkinson's patients ub-312 is first immunotherapy to show reduction of pathological alpha-synuclein in cerebrospinal fluid of parkinson's patients

VAXX Ratings Summary

VAXX Quant Ranking